Phase I Double-Blind, Randomized, Placebo-Controlled Trial of GZ21T for Safety, Tolerability, and Pharmacokinetics in Actinic Keratosis

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of single ascending topical doses of GZ21T in healthy volunteers. This is clinically relevant as it aims to establish the foundational safety profile and pharmacokinetic parameters of GZ21T, which is crucial for its potential future application in treating **actinic keratosis**. Understanding these parameters is essential for determining appropriate dosing regimens and ensuring patient safety in subsequent clinical trials.

The clinical trial focuses on participants diagnosed with **actinic keratosis**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed. The selection process for the trial population remains unspecified.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** Phase I study aimed at evaluating the safety, tolerability, and pharmacokinetics of single ascending topical doses of GZ21T in healthy volunteers. The trial targets individuals with **actinic keratosis** and is scheduled to commence recruitment on July 29, 2024, with an estimated completion date of March 31, 2025. The study will involve a series of visits, beginning with an inclusion visit where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will be randomized to receive either the investigational product or a placebo in a blinded manner. The trial will include multiple follow-up visits to monitor the participants' response to the treatment, assess safety parameters, and collect pharmacokinetic data. These visits are crucial for evaluating the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational product's effects.

The expected duration of participant involvement will vary depending on the specific dosing schedule and follow-up requirements, but it is anticipated to last several months. Participants may be withdrawn from the study early if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The trial's design ensures rigorous monitoring and adherence to ethical standards, with the primary goal of advancing the understanding of GZ21T's potential therapeutic benefits for individuals with actinic keratosis.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on July 29, 2024, with an estimated completion date of March 31, 2025. Efficacy assessments will be conducted at predetermined intervals throughout the trial period. The specific parameters or endpoints for evaluating efficacy have not been detailed in the available data. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that efficacy is measured accurately and consistently. The methods and tools for collecting and analyzing efficacy data are not specified in the provided information. The trial's design and execution will follow established clinical protocols to ensure the reliability and validity of the efficacy outcomes.